Compare AFLAC Incorporated (AFL) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs Davita Inc — how do they compare? AFLAC Incorporated trades at $122.08 (market cap $61.13B), while Davita Inc trades at $178.34 (market cap $11.72B). The key difference: AFLAC Incorporated is far larger — about 5.2× Davita Inc's market cap, and AFLAC Incorporated pays a 2% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| AFL | DVA | |
|---|---|---|
Market Cap | $61.13B | $11.72B |
Sector | Financials | Health |
52-Week High | $129.55 | $240.96 |
52-Week Low | $103.55 | $103.87 |
Enterprise Value | $71.08B | $24.44B |
Dividend Yield | 2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aflac (AFL) trades at $124.61, down 1.62% with recent earnings misses and bearish technical signals. The stock shows mixed fundamentals with a P/E of 13.44 and net income margin of 26.79%, though revenue declined to $17.36B in 2025. Recent news highlights Japan unit challenges and dividend reliability, with the company maintaining 43 consecutive years of dividend increases.
Outlook remains cautious with analyst consensus at Hold (56.24%) and price target of $117.60 below current levels. Key risks include foreign exchange headwinds and competitive pressures, while the dividend yield and strong cash flow provide support for income-focused investors amid near-term volatility.
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
